Enanta Pharmaceuticals, Inc.
ENTADrugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
EDP-938
Respiratory Syncytial Virus
EDP-938 Dose 1
RSV Infection
EDP-235
COVID-19
EDP-305 1 mg
Primary Biliary Cholangitis
EDP-305 Dose 1
Non-Alcoholic Steatohepatitis
EDP-323 Dose Regimen 1
RSV Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDP-938 | Phase 2 | Respiratory Syncytial Virus | - | - |
EDP-938 Dose 1 | Phase 2 | RSV Infection | - | - |
EDP-235 | Phase 2 | COVID-19 | - | - |
EDP-305 1 mg | Phase 2 | Primary Biliary Cholangitis | - | - |
EDP-305 Dose 1 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
EDP-323 Dose Regimen 1 | Phase 2 | RSV Infection | - | - |
RSV Infection
1 drug in this indication
COVID-19
1 drug in this indication
Respiratory Syncytial Virus
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
Non-Alcoholic Steatohepatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)